V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330010857 | 330005756 | 1.84 | null | Palliative (P) | 2013-09-12 | 2013-09-19 | Cyclophosphamide High Dose | Y | N | 330023409 | CYTARABINE |
| 330010858 | 330005756 | 1.68 | 67 | Palliative (P) | 2013-12-28 | 2014-01-04 | Bortezomib +/- Dexamethasone | 02 | N | 330023409 | FLUOROURACIL + MITOMYCIN |
| 330010859 | 330010961 | 1.7 | 57.9 | Palliative (P) | 2017-02-25 | 2017-02-26 | Cyclophosphamide High Dose | N | N | 330023440 | CARBOPLATIN + CETUXIMAB + FU |
| 330010860 | 330005758 | 1.58 | 82 | Curative (C) | 2017-01-08 | 2017-01-08 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 330023454 | POMB |
| 330010861 | 330005761 | 1.48 | null | null | 2013-10-24 | 2013-10-24 | BEP 5 Day | 2 | N | 330023516 | AML18 TRIAL |
| 330010862 | 330011969 | 1.62 | 39.3 | Palliative (P) | 2013-12-25 | 2014-01-18 | CHLORAMBUCIL + RITUXIMAB | 2 | N | 330023522 | UKALL2014 |
| 330010863 | 330005763 | 1.76 | 19.7 | Neo-adjuvant (N) | 2016-06-12 | 2016-06-19 | DOXORUBICIN + METHOTREXATE | N | N | 330023532 | DHAP - R |
| 330010864 | 330005764 | 0 | 113 | Palliative (P) | 2013-10-22 | 2013-10-22 | Cyclophosphamide High Dose | N | N | 330023539 | CVP |
| 330010865 | 330005767 | 1.7 | 69 | null | 2016-05-22 | 2017-08-01 | Hydroxycarbamide | 02 | N | 330023548 | BORTEZOMIB + CYTARABINE + RITUXIMAB |
| 330010866 | 330005769 | null | 87.75 | null | 2014-08-02 | 2014-10-02 | UKALL14- Intens/CNS Proph | N | N | 330023561 | PAC-E |
| 330010867 | 330009146 | 1.56 | 61.5 | Curative (C) | 2013-08-16 | 2013-08-20 | ALL Int Guide A/B/C Maint Ph V | 2 | N | 330023606 | GEMCITABINE |
| 330010868 | 330005773 | 1.67 | 83 | Palliative (P) | 2017-12-04 | 2017-12-14 | Hydroxycarbamide | N | N | 330023624 | MITOTANE |
| 330010869 | 330005773 | 1.77 | 95.9 | Disease modification (D) | null | 2014-12-09 | CARBOPLATIN + CETUXIMAB + FU | N | N | 330023624 | CYTARABINE |
| 330010870 | 330005774 | null | 35.1 | Palliative (P) | 2013-05-31 | 2013-09-29 | Cladribine (subcut) 5 days | N | N | 330023647 | UKALL2014 |
| 330010871 | 330005777 | 0 | 91 | Palliative (P) | 2016-10-16 | 2017-01-13 | PAC-E | Y | N | 330023669 | CYCLOPHOSPHAMIDE |
| 330010872 | 330009150 | 1.51 | 0 | Palliative (P) | 2015-04-15 | 2015-04-15 | Pazopanib | N | N | 330023693 | IVA |
| 330010873 | 330009151 | 1.59 | 67 | Disease modification (D) | 2015-11-02 | 2015-12-11 | Capecitabine (14 days)+Carboplatin | N | N | 330023705 | BLEOMYCIN + CISPLATIN + ETOPOSIDE |
| 330010874 | 330012880 | 1.81 | 79.3 | Neo-adjuvant (N) | 2016-12-22 | 2017-05-25 | DHAP | N | N | 330023722 | IBRUTINIB |
| 330010875 | 330005781 | 0 | 93.2 | null | 2016-01-19 | 2016-03-12 | Topotecan (intravenous) | N | N | 330023723 | IMATINIB |
| 330010876 | 330005783 | 1.65 | 58.4 | Adjuvant (A) | 2016-04-24 | 2016-11-28 | EMA/CO | 2 | N | 330023743 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330010877 | 330005785 | 0 | 41.5 | Palliative (P) | null | 2014-03-14 | Doxorubicin + Methotrexate | null | null | 330023744 | CARBOPLATIN + VINCRISTINE |
| 330010878 | 330010970 | 1.8 | 63 | Curative (C) | 2018-01-06 | 2018-03-31 | CETUXIMAB + CISPLATIN + FU | N | null | 330023758 | AML19 TRIAL |
| 330010879 | 330005788 | 1.79 | 0 | Curative (C) | 2015-08-30 | 2015-08-30 | BLEOMYCIN + VINCRISTINE | N | N | 330023765 | LI-1 TRIAL |
| 330010880 | 330005788 | 1.79 | 45.6 | Neo-adjuvant (N) | 2017-02-15 | 2017-04-03 | IVA | N | null | 330023765 | VIDE |
| 330010881 | 330005791 | null | 0 | Palliative (P) | 2015-02-09 | 2015-02-23 | DACTINOMYCIN + CYCLO + VINCRISTINE | N | null | 330023808 | CAPECITABINE + GEMCITABINE |
| 330010882 | 330010974 | null | 78.8 | Palliative (P) | 2015-09-06 | 2015-09-07 | Ipilimumab | N | N | 330023810 | ALL INTERIM GUIDELINES |
| 330010883 | 330005792 | 0 | 8.4 | Neo-adjuvant (N) | 2017-01-13 | 2017-04-21 | VIDE | null | null | 330023816 | UKALL 2003 |
| 330010884 | 330005792 | 1.83 | 83.8 | Neo-adjuvant (N) | 2014-12-13 | 2014-12-13 | Carboplatin + Cetux + FU (>Cycle 2) | 02 | N | 330023816 | CARBOPLATIN + DOXORUBICIN |
| 330010885 | 330005793 | 1.67 | 109.2 | Curative (C) | 2013-01-06 | 2013-12-17 | EMA/CO | N | N | 330023819 | CLADRIBINE |
| 330010886 | 330005796 | 1.56 | 64.5 | Curative (C) | 2015-10-29 | 2015-10-29 | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | N | N | 330023842 | CISPLATIN + PACLITAXEL |
| 330010887 | 330005798 | 1.64 | 67.1 | Palliative (P) | 2013-07-02 | 2013-07-03 | Cisplatin+Doxorubicin+Etoposide 28d | 2 | N | 330023851 | FIGARO TRIAL |
| 330010888 | 330005801 | 0 | 60.55 | Disease modification (D) | 2016-04-06 | 2016-04-18 | ETOPOSIDE + IFOSFAMIDE + MTX | 02 | N | 330023868 | VDC |
| 330010889 | 330005805 | 0 | 80.5 | Palliative (P) | 2013-06-03 | 2013-06-08 | CTD | 02 | N | 330023874 | TOPOTECAN |
| 330010891 | 330005808 | 1.69 | 98.9 | Palliative (P) | 2017-04-11 | 2017-04-11 | Alemtuz+Fludara+Melphalan RIC MUD | 2 | N | 330023886 | DACARBAZINE |
| 330010892 | 330009164 | null | 85.9 | Palliative (P) | 2015-03-01 | 2015-03-09 | IDARUBICIN | 01 | N | 330023923 | IVA |
| 330010893 | 330005812 | 1.55 | 11.2 | null | 2018-03-31 | 2018-03-31 | Dox + HD Mtx (post PAM) | 02 | N | 330023929 | PEMBROLIZUMAB |
| 330010894 | 330005813 | 1.55 | 65 | Neo-adjuvant (N) | 2014-10-25 | 2014-11-23 | CYCLOPHOSPHAMIDE | N | null | 330023933 | EP |
| 330010895 | 330005817 | 1.52 | 103 | Curative (C) | 2018-02-26 | 2018-02-26 | CNS HGG Bevacizumab + Irinotecan | N | null | 330023935 | DOXORUBICIN + OLARATUMAB |
| 330010896 | 330009167 | 1.76 | 76.1 | Curative (C) | 2016-06-13 | 2016-06-13 | AML 18 TRIAL | N | N | 330023942 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330010897 | 330009167 | 0 | null | null | 2016-10-01 | 2016-10-03 | Temozolomide + RT | N | N | 330023942 | UKALL2014 |
| 330010898 | 330009168 | 1.79 | 24.5 | Palliative (P) | null | 2016-05-27 | IVADo | null | N | 330023962 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330010899 | 330005822 | 1.65 | 65 | Curative (C) | 2014-03-25 | 2014-03-25 | Dacarbazine | N | N | 330023981 | TRASTUZUMAB |
| 330010900 | 330005824 | null | 71.5 | Curative (C) | 2017-05-24 | 2017-06-22 | VIDE | N | null | 330023994 | CLOFARABINE + CYTARABINE |
| 330010901 | 330005824 | null | 28.4 | Palliative (P) | 2013-07-24 | 2013-07-31 | EMA | N | N | 330023994 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330010902 | 330005828 | 1.62 | 50 | Palliative (P) | null | 2017-08-11 | CVP R | null | N | 330024004 | POMB |
| 330010903 | 330005831 | 1.8 | 35.75 | Palliative (P) | 2014-02-03 | 2014-02-10 | VINCRISTINE | 2 | Y | 330024059 | EDP |
| 330010904 | 330005831 | null | 60.2 | null | 2017-04-23 | 2017-04-24 | PAC-PLAT | N | N | 330024059 | FCR |
| 330010905 | 330005834 | 1.67 | 66 | Palliative (P) | null | 2018-09-18 | TIP | N | N | 330024100 | CISPLATIN + FLUOROURACIL + RT |
| 330010906 | 330005835 | 1.7 | 80.6 | Adjuvant (A) | 2014-12-06 | 2014-12-06 | CHOP R - 21 days | N | N | 330024112 | SUNITINIB |
| 330010907 | 330005836 | 1.69 | 62.3 | Adjuvant (A) | 2017-07-29 | 2017-08-11 | MYELOMA XI TRIAL | 2 | null | 330024122 | IMATINIB |